Endocrine therapy metastatic prostate cancer;Traitement hormonal du cancer de la prostate métastatique

Progres en Urologie

Volumn 13, Issue 2, 2003, Pages 334-341

  Ruffion, Alain ^a   Fontaine, Eric ^b   Staerman, Frédéric ^c  

^a Hopital Henry Gabrielle   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c SERVICE DE DERMATOLOGIE   (France)

Author keywords

Cancer; Endocrine therapy; Metastases; Prostate

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; LUTEINIZING HORMONE; NILUTAMIDE;

CASTRATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; METASTASIS; MONOTHERAPY; ORCHIECTOMY; PROSTATE CANCER; REVIEW; DRUG ANTAGONISM; DRUG POTENTIATION; MALE; PATHOLOGY; PROSTATE TUMOR;

GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 0042709928     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Immediate versus deferred treatment for advanced prostatic cancer : initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br. J. Urol., 1997 ; 79 : 235-246.
2. Maximum androgen blockade in advanced prostate cancer : an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet, 1995 ; 346 : 265-269.
3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group [see comments]. Lancet, 2000 ; 355 : 1491-1498.
4. BALES G.T., CHODAK G. W. : A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology, 1996 ; 47 : 38-43.
5. BAYOUMI A.M., BROWN A.D., GARBER A.M. : Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl. Cancer Inst., 2000 ; 92 : 1731-1739.
6. BOCCON-GIBOD L. : Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer ? Eur. Urol., 1998 ; 33 : 159-164.
7. BOCCON-GIBOD L., FOURNIER G., BOTTET P., MARECHAL J.M., GUITER J., RISCHMANN P., HUBERT J., SORET J.Y., MANGIN P., MALLO C., FRAYSSE C.E. : Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur. Urol., 1997 ; 32 : 391-395.
8. BOUCHOT O., LENORMAND L., KARAM G., PRUNET D., GASCHIGNARD N., MALINOVSKY J.M., BUZELIN J.M. : Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur. Urol., 2000 ; 38 : 543-549.
9. BRUCHOVSKY N., RENNIE P.S., COLDMAN AJ.., GOLDEN-BERG S.L., TO M., LAWSON D. : Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 1990; 50: 2275-2282.
10. BYAR D.P. : The Veterans Administration Cooperative Urological Research Group's studies of the cancer of the prostate. Cancer, 1973; 32 : 1126-1138.
11. CHANG A., YEAP B., DAVIS T., BLUM R., HAHN R., KHANNA O., FISHER H., ROSENTHAL J., WITTE R., SCHINELLA R., TRUMP D. : Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J. Clin. Oncol., 1996 ; 14 : 2250-2257.
12. CHENG L., ZINCKE H., BLUTE M.L., BERGSTRAHL E.J., SCHERER B., BOSTWICK D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer, 2001 ; 91 : 66-73.
13. CONROY T., MALISSARD L., DARTOIS D., LUPORSI E., STINES J., CHARDOT C. Natural history and development of bone metastasis. Apropos of 429 cases. Bull Cancer, 1988 ; 75 : 845-857.
14. CRAWFORD E.D., EISENBERGER M.A., McLEOD D. G., SPAULDING J.T., BENSON R., DORR F., BLUMENSTEIN B.A., DAVIS M.A., GOODMAN P.J.. : A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 1989 ; 321 : 419-424.
15. CROOK J.M., SZUMACHER E., MALONE S., HUAN S., SEGAL R. : Intermittent androgen suppression in the management of prostate cancer. Urology, 1999 ; 53 : 530-534.
16. DANIELL H.W. : Osteoporosis after orchiectomy for prostate cancer. J. Urol., 1997 ; 157 : 439-444.
17. DANIELL H.W., DUNN S.R., FERGUSON D.W., LOMAS G., NIAZI Z., STRATTE P.T. : Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol., 2000 ; 163 : 181-186.
18. DATTA S.N., THOMAS K. AND MATTHEWS P.N. : Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate ? J. Urol., 1997 ; 158 : 175-177.
19. DE LA TAILLE A., ZERBIB M., CONQUY S., AMSELLEM-OUAZANA D., SAIGHI D., DEBRE B. Etude de l'hormonothérapie intermittente chez les patients présentant une récidive biologique après prostatectomie radicale ou radiothérapie. Prog. Urol., 2002 ; 12 : 240-247.
20. DE VOOGT H.J., STUDER U., SCHRODER F.H., KLIJN J.G., DE PAUW M., SYLVESTER R. : Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group. Eur. Urol., 1998 ; 33 : 152-158.
21. DECENSI A.U., BOCCARDO F., GUARNERI D., POSITANO N., PAOLETTI M.C., COSTANTINI M., MARTORANA G., GIULIANI L. : Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J. Urol., 1991 ; 146 : 377-381.
22. DENIS L.J., KEUPPENS F., SMITH PH., WHELAN P., DE MOURA J.L., NEWLING D., BONO A., SYLVESTER R. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur. Urol., 1998 ; 33 : 144-151.
23. DI SILVERIO F., SCIARRA F, D'ERAMO G. : Advanced prostatic cancer : clinical and hormonal response to flutamide in patients pre-treated with LHRH analogue and cyproterone acetate. Eur. Urol., 1990 ; 18 : 10-15.
24. DIJKMAN G.A., JANKNEGT R.A., DE REIJKE T.M., DEBRUYNE F.M. : Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J. Urol., 1997 ; 158 : 160-163.
25. DRUMMOND M., O'BRIEN B. : Methods for the Economic Evaluation of Health Care Programmes. G. a. T. Stoddart, George eds. Oxford, Oxford University Press, 1997.
26. EISENBERGER M.A., BLUMENSTEIN B.A., CRAWFORD E.D., MILLER G., MCLEOD D.G., LOEHRER P.J., WILDING G., SEARD K., CULKIN D.J., THOMPSON LM., BUES A.J., LOWE B.A. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med., 1998 ; 339 : 1036-1042.
27. FELDMAN H.A., GOLDSTElN L, HATZICHRISTOU D.G., KRANE R.J., MCKINLAY J.B. Impotence and its medical and psychosocial correlates : results of the Massachusetts Male Aging Study. J. Urol., 1994 ; 151 : 54-61.
28. FERNANDEZ PENA C.M., MORANO AMADO L.E., MONTES SANTIAGO J., FACHAL C. Fulminant liver failure with a fatal outcome due to flutamide. Med. Clin. (Barc), 1997 ; 108 : 237-238.
29. FRIEDMAN G., LAMOUREUX E., SHERKER A.H. : Fatal fulminant hepatic failure due to cyproterone acetate. Dig. Dis. Sci., 1999 ; 44 : 1362-1363.
30. HALL M.C., FRITZSCH R.J., SAGALOWSKY A.I., AHRENS A., PETTY B., ROEHRBORN C.G. : Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology, 1999 ; 53 : 898-902.
31. HEDLUND P.O. : Side effects of endocrine treatment and their mechanisms : castration, antiandrogens, and estrogens. Prostate Suppl., 2000 ; 10 : 32-37.
32. HILLNER B.E., MCLEOD D.G., CRAWFORD E.D., BENNETT C.L. : Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology, 1995 ; 45 : 633-640.
33. IVERSEN P. : Antiandrogen monotherapy : indications and results. Urology, 2002 ; 60 : 64-71.
34. IVERSEN P., RASMUSSEN F., KLARSKOV P., CHRISTENSEN I.J. : Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer, 1993 ; 72 : 3851-3854.
35. IVERSEN P., TVETER K., VARENHORST E. : Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand. J. Urol. Nephrol., 1996 ; 30 : 93-98.
36. IVERSEN P., TYRRELL C.J., KAISARY A.V., ANDERSON J.B., VAN POPPEL H., TAMMELA T.L., CHAMBERLAIN M., CARROLL K., MELEZINEK I. : Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer : 6.3 years of followup. J. Urol., 2000 ; 164 : 1579-1582.
37. JANKNEGT R.A., ABBOU C.C., BARTOLETTI R., BERNSTEINHAHN L., BRACKEN B., BRISSET J.M., DA SILVA P.C., CHISHOLM G., CRAWFORD E;D., DEBRUYNE F.M.: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urol., 1993 ; 149: 77-82.
38. KAISARY A.V., TYRRELL C.J., BEACOCK C., LUNGLMAYR G., DEBRUYNE F. A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Eur. Urol., 1995 ; 28 : 215-222.
39. KARLING P., HAMMAR M., VARENHORST E. : Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J. Urol., 1994 ; 152 : 1170-1173.
40. LABRIE F., DUPONT A., BELANGER A., CUSAN L., LACOUR CIERE Y., MONFETTE G., LABERGE J.G., EDMOND J.P., FAZEKAS A.T., RAYNAUD J.P., HUSSON J.M. New hormonal therapy in prostatic carcinoma : combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med., 1982 ; 5 : 267-275.
41. LAUFER M., DENMEADE S.R., SINIBALDI V.J., CARDUCCI M.A., EISENBERGER M.A. : Complete androgen blockade for prostate cancer : what went wrong ? J. Urol., 2000 ; 164 : 3-9.
42. LUND F., RASMUSSEN F. : Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br. J. Urol., 1988 ; 61 : 140-142.
43. MARIANI A.J., GLOVER M., ARITA S. : Medical versus surgical androgen suppression therapy for prostate cancer : a 10-year longitudinal cost study. J. Urol., 2001 ; 165 : 104-107.
44. MCCAFFREY J.A., SCHER H.I. : Interstitial pneumonitis following bicalutamide treatment for prostate cancer. J. Urol., 1998 ; 160 : 131.
45. MESSING E.M., MANOLA J., SAROSDY M. : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med., 1999 ; 341 : 1781-1788.
46. MILBANK A.J., DREICER R., KLEIN E.A. : Hormonal therapy for prostate cancer : primum non nocere. Urology, 2002 ; 60 : 738-741.
47. PFITZENMEYER P., FOUCHER P., PIARD F., COUDERT B., B RAUD M.L., GABEZ P., LACRIOIX S., MABILLE J.P., CAMUS P. : Nilutamide pneumonitis : a report on eight patients. Thorax, 1992 ; 47 : 622-627.
48. SATO N., GLEAVE M.E., BRUCHOVSKY N.,RENNIE P.S., GOLDENBERD S.L., LANGE P.H., SULLIVAN L.D. : Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J. Steroid. Biochem. Mol. Biol., 1996 ; 58 : 139-146.
49. SCHMITT B., BENNETT C., SEIDENFELD J., SAMSON D., WILT T. : Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst. Rev., 2000, CD001526.
50. SCHRODER F.H. : Endocrine treatment of prostate cancer - recent developments and the future. Part 1 : maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU Int., 1999 ; 83 : 161-170.
51. SCHRÖDER F.H., COLLETTE L., DE REIJKE T.M., WHELAN P.: Prostate cancer treated by anti-androgens: is sexual function preserved ? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br. J. Cancer, 2000 ; 82 : 283-290.
52. SEE W.A., WIRTH M.P., McLEOD D.G., IVERSEN P., KLIMBERG P., GLEASON D., CHODAK G., MONTIE J., RYRRELL C., WALLACE D.M., DELAERE K.P., VAAGE S., TAMMELA T.L., LUKKARINEN O., PERSSON B.E., CARROLL K., KOLVENBAG G.J. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer : first analysis of the early prostate cancer program. J. Urol., 2002 ; 168 : 429-435.
53. SEIDENFELD J., SAMSON D.J., HASSELBLAD V., AARONSON N., ALBERTSEN P.C., BENNETT C.L., WILT T.J. : Single-therapy androgen suppression in men with advanced prostate cancer : a systematic review and meta-analysis. Ann. Intern. Med., 2000 ; 132 : 566-577.
54. SGRIGNOLI A.R., WALSH P.C., STEINBERG G.D., STEINER M.S., EPSTEIN J.I. : Prognostic factors in men with stage D1 prostate cancer : identification of patients less likely to have prolonged survival after radical prostatectomy. J. Urol., 1994 ; 152 : 1077-1081.
55. SIEBER P.R., KEILLER R., KAHNOSKI R.J., GARCIA-VARGAS J.E., GALLO J., MCFADDEN S. Bone mineral density is maintained during bicalutamide (Casodex) treatment. S. Grunberg ed. Orlando, ASCO meeting, 2002.
56. STEGE R. : Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl., 2000 ; 10 : 38-42.
57. STRUM S.B., MCDERMED J.E., SCHOLZ M.C., JOHNSON H, TISMAN G. : Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br. J. Urol., 1997 ; 79 : 933-941.
58. TARLE M., AHEL M.Z., KOVACIC K. : Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res., 2002 ; 22 : 2525-2529.
59. TRACHTENBERG J., GITTLEMAN M., STEIDLE C., B ARZELL W., FRIEDEL W., PESSIS D., FOTHERINGHAM N., CAMPION M., GARNICK M.B. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol., 2002 ; 167 : 1670-1674.
60. TYRRELL C.J., KAISARY A.V., IVERSEN P., ANDERSON J.B., B AERT L., TAMMELA T., CHAMBERLAIN M., WEBSTER A., BLACKEDGE G. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol., 1998 ; 33 ; 447-456.
61. WALSH P.C., DEWEESE T.L., EISENBERGER M.A. : A structured debate : immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J. Urol., 2001 ; 166 : 508-515.
62. WONG P.W., MACRIS N., DIFABRIZIO L., SERIFF N;S. Eosinophilic lung disease induced by bicalutamide : a case report and review of the medical literature. Chest., 1998 ; 113 : 548-550.
63. ZALCBERG J.R., RAGHAVEN D., MARSHALL V., THOMSON P.J. : Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate-an Australian multicentre trial. Br. J. Urol., 1996 ; 77 : 865-869.